The Paradigm Shift from Traditional Scientific Platforms to Integrated Communications Plans

In the rapidly evolving biopharma landscape, the approach to scientific communications is undergoing a significant transformation. The shift from traditional scientific platforms to integrated communications plans (ICPs) is becoming increasingly crucial for ensuring cohesive and impactful messaging. This article delves into the components, implementation, and benefits of an ICP tailored for the biopharma industry, addressing the challenges of fragmented messaging and the need for a unified communication strategy...
Read More

Top Stories

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Involve Medical Affairs in insight management, early phases of clinical trials, etc.

It’s Never Too Soon: How and When to

Engagement with Medical Affairs is critical at every...
Health Literacy Month

Celebrating Health Literacy Month 2024:

October is Health Literacy Month, a reminder of the...
What do HCPs want?

What do Healthcare Professionals Want from Medical Affairs Post COVID-19?

Here's an interesting read for medical affairs teams on how to cater to the digital...
HCP engagement

A 4-Step Plan to Drive HCP Engagement

HCPs are a time-constrained and hard-to-engage audience. Learn how pharma can digitally engage HCPs better...
diversity and inclusion

Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy

Read this update on how the New England Journal of Medicine is trying to promote...

MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)

An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.